Evaluation of short-term efficacy of extraspinal cementoplasty for bone metastasis: A monocenter study of 31 patients
- PMID: 30591867
- PMCID: PMC6303380
- DOI: 10.1016/j.jbo.2018.09.004
Evaluation of short-term efficacy of extraspinal cementoplasty for bone metastasis: A monocenter study of 31 patients
Abstract
Objective: To study the effect on pain of per-cutaneous cementoplasty for painful extraspinal bone metastasis.
Method: 43 patients with extraspinal bone metastasis were included between April 2006 and October 2014 in this retrospective monocenter study. The primary endpoint was pain level measured on a 0-10 numeric rating scale at week 1 after cementoplasty as compared with pre-cementoplasty. Secondary endpoints were long-term pain level and impact on quality of life and disability.
Results: Mean pain score was 4.2 (SD ±3.6) before cementoplasty and 1.09 (SD ±2.4) at week 1 (p = 0.005) (n = 31 patients). At 22 months after cementoplasty, quality of life and disability improved (according to the patient global assessment) for 47.6% and 52.2% of patients (n = 21patients). We did not find a predictor of good response. Cement leakage was the most common adverse event.
Conclusion: Percutaneous cementoplasty of extraspinal bone metastasis is a rapidly efficient treatment with few adverse events. Its efficacy persists over time, with a benefit for disability and quality of life. Although this technique is only palliative, it should be considered in this situation.
Keywords: Bone metastasis; Pain management; Percutaneous cementoplasty.
Figures
References
-
- Costa L., Badia X., Chow E., Lipton A., Wardley A. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support. Care Cancer. 2008;16:879–889. - PubMed
-
- Chow E., Zeng L., Salvo N., Dennis K., Tsao M., Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin. Oncol. 2012;24:112–124. - PubMed
-
- McQuay H.J., Carroll D., Moore R.A. Radiotherapy for painful bone metastases: a systematic review. Clin. Oncol. 1997;9:150–154. - PubMed
-
- Brantus J.-F., Roemer-Becuwe C., Cony-Makhoul P., Salino S., Fontana A., Debourdeau P. Guide de recommandations d'utilisation des bisphosphonates dans les lésions osseuses malignes des tumeurs solides et du myélome multiple. Rev. Méd. Intern. 2011;32:494–505. - PubMed
-
- Henry D., Von Moos R., Vadhan-Raj S., Hungria V., Spencer A., Hirsh V. 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur. J. Cancer Suppl. 2009;7:12. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
